Abstract

BackgroundThe successful application of—omics technologies in the discovery of novel biomarkers and targets of therapeutic interventions is facilitated by large collections of well curated clinical samples stored in bio banks. Mining the plasma proteome holds promise to improve our understanding of disease mechanisms and may represent a source of biomarkers. However, a major confounding factor for defining disease-specific proteomic signatures in plasma is the variation in handling and processing of clinical samples leading to protein degradation. To address this, we defined a plasma proteolytic signature (degradome) reflecting pre-analytical variability in blood samples that remained at ambient temperature for different time periods after collection and prior to processing.MethodsWe obtained EDTA blood samples from five healthy volunteers (n = 5), and blood tubes remained at ambient temperature for 30 min, 8, 24 and 48 h prior to centrifugation and isolation of plasma. Naturally occurred peptides derived from plasma samples were compared by label-free quantitative LC–MS/MS. To profile protein degradation, we analysed pooled plasma samples at T = 30 min and 48 h using PROTOMAP analysis. The proteolytic pattern of selected protein candidates was further validated by immunoblotting.ResultsA total of 820 plasma proteins were surveyed by PROTOMAP, and for 4 % of these, marked degradation was observed. We show distinct proteolysis patterns for talin-1, coagulation factor XI, complement protein C1r, C3, C4 and thrombospondin, and several proteins including S100A8, A9, annexin A1, profiling-1 and platelet glycoprotein V are enriched after 48 h blood storage at ambient temperature. In particular, thrombospondin protein levels increased after 8 h and proteolytic fragments appeared after 24 h storage time.ConclusionsThe overall impact of blood storage at ambient temperature for variable times on the plasma proteome and degradome is relatively minor, but in some cases can cause a potential bias in identifying and assigning relevant proteomic markers. The observed effects on the plasma proteome and degradome are predominantly triggered by limited leucocyte and platelet cell activation due to blood handling and storage. The baseline plasma degradome signature presented here can help filtering candidate protein markers relevant for clinical biomarker studies.Electronic supplementary materialThe online version of this article (doi:10.1186/s12014-016-9126-9) contains supplementary material, which is available to authorized users.

Highlights

  • The successful application of—omics technologies in the discovery of novel biomarkers and targets of therapeutic interventions is facilitated by large collections of well curated clinical samples stored in bio banks

  • Biobanks as a source of biological samples with associated clinical and demographic data are essential for the study of disease mechanisms and for the discovery of novel biomarkers and targets of therapeutic interventions [1]

  • The purpose of UK quality in organ donation (QUOD) biobank is to provide a comprehensive collection of clinical samples, obtained during deceased donor organ management, for research on organ donation and transplantation

Read more

Summary

Introduction

The successful application of—omics technologies in the discovery of novel biomarkers and targets of therapeutic interventions is facilitated by large collections of well curated clinical samples stored in bio banks. A major confounding factor for defining disease-specific proteomic signatures in plasma is the variation in handling and processing of clinical samples leading to protein degradation. Biobanks as a source of biological samples with associated clinical and demographic data are essential for the study of disease mechanisms and for the discovery of novel biomarkers and targets of therapeutic interventions [1]. Proteomic technologies have been employed for the discovery of biomarkers and novel targets of interventions in diverse fields of medicine In such studies, there are many variables that can influence the outcome of mass spectrometry based serum/plasma proteomics [12, 13]. As keeping blood at ambient temperature does minimise platelet and complement activation and since these conditions are more applicable in a clinical setting, we set out to systematically profile the plasma degradome at variable blood storage times

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call